Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing

Charles River Laboratories International, Inc. (NYSE: CRL) and Toxys today announced a collaboration that offers Charles River’s clients access to ReproTracker®, a state-of-the-art human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008659993/en/

As leveraged in the use of developmental and reproductive toxicology (DART) studies, ReproTracker complements traditional toxicology methods and is used to investigate if compounds interfere with early embryonic development, and the assay can quantitatively predict their teratogenic potential. ReproTracker can be used as an early-phase developmental toxicity screening platform, an alternative for animal-free teratogenicity testing of pharmaceuticals and (agro) chemicals, or as a tool to extrapolate animal-derived results to humans.

“ReproTracker is a one-of-a-kind in vitro solution to enable safe and effective developmental toxicity testing,” said Elise Lewis, PhD, ATS, Principal Director and Global Lead, DART (Pharmaceuticals), Charles River. “DART is a critical step in the nonclinical phase of drug and chemical development, and we are pleased to offer our clients access to a tool that can help ensure the safety of patients and consumers.”

Amer Jamalpoor, Chief Scientific Officer at Toxys, added, “Our collaboration with Charles River enables us to accelerate the adoption of ReproTracker and strengthen its validation as a valuable non-animal alternative to classical in vivo approaches for DART.”

This collaboration is the latest addition to Charles River’s robust DART offerings, which span pharmaceuticals (including vaccines, biopharmaceuticals, and veterinary and medical devices) agrochemicals, industrial chemicals, and food additives. Charles River maintains an extensive historical control database to aid in data interpretation and to help inform future client studies. As part of Charles River’s Alternative Methods Advancement Project™ (AMAP™), access to ReproTracker reinforces Charles River’s commitment to incorporating New Approach Methodologies (NAMs) when possible, supporting the 3Rs (Replacement, Reduction and Refinement) while maintaining the highest standards of patient safety.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Toxys

Toxys is a Dutch biotechnology company, dedicated to improving chemical safety through innovative, animal-free testing solutions. Toxys develops advanced in vitro assays that help identify toxic, carcinogenic and reproductive toxicological properties of chemicals early in development. With a strong commitment to scientific excellence and sustainability, Toxys is shaping the future of toxicology by offering reliable, ethical, and cost-effective alternatives for safety testing. The company collaborates with leading research institutions and regulatory bodies worldwide and continues to expand its global footprint through strategic partnerships and product innovation.

DART is a critical step in the nonclinical phase of drug and chemical development, and we are pleased to offer our clients access to a tool that can help ensure the safety of patients and consumers.

Contacts

Charles River Investor Contact:

Todd Spencer

Corporate Vice President,

Investor Relations

781.222.6455

todd.spencer@crl.com



Charles River Media Contact:

Amy Cianciaruso

Corporate Senior Vice President,

Chief Communications Officer

781.222.6168

amy.cianciaruso@crl.com



Toxys Media Contact:

Paula van Rossum

Chief Business Officer

+31 71 3322470

p.vanrossum@toxys.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.